GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Biological: Otelixizumab
Biological: Placebo

First Posted Date: 2013-12-04

Last Posted Date: 2019-06-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT02000817

Locations: 🇧🇪
GSK Investigational Site, Liège, Belgium

Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.

Phase 1

Terminated

Conditions: Colitis, Ulcerative

Interventions: Drug: GSK2586184 400mg

First Posted Date: 2013-12-04

Last Posted Date: 2020-10-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2

Registration Number: NCT02000453

Locations: 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Phase 2

Completed

Conditions: Glomerulosclerosis, Focal Segmental

Interventions: Drug: Losmapimod

First Posted Date: 2013-12-04

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 17

Registration Number: NCT02000440

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

FluLaval® Quadrivalent Pregnancy Registry

Withdrawn

Conditions: Influenza

Interventions: Other: Data collection

First Posted Date: 2013-12-04

Last Posted Date: 2014-10-27

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02000466

A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects

Phase 1

Completed

Conditions: Infections, Respiratory Tract

Interventions: Drug: GSK2140944 for Injection
Drug: GSK2140944 Capsule

First Posted Date: 2013-12-04

Last Posted Date: 2017-07-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT02000765

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Investigational H7N9 vaccine GSK3206641A
Biological: Investigational H7N9 vaccine GSK3206640A
Biological: Placebo

First Posted Date: 2013-12-03

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 424

Registration Number: NCT01999842

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

Not Applicable

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Procedure: Nasal swab sampling
Procedure: Blood sampling
Other: Diary cards

First Posted Date: 2013-11-26

Last Posted Date: 2022-11-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2409

Registration Number: NCT01995175

Locations: 🇹🇭
GSK Investigational Site, Pathum Thani, Thailand

Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Acellular Pertussis

Interventions: Biological: Boostrix™

First Posted Date: 2013-11-20

Last Posted Date: 2018-08-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 302

Registration Number: NCT01988857

Locations: 🇻🇳
GSK Investigational Site, Hanoi, Vietnam

Study to Investigate the Irritation Potential of GSK1940029 Gel

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: 0.3% GSK1940029 gel
Drug: 1% GSK1940029 gel
Drug: 0.3%/1% vehicle gel only
Other: Sterile distilled water
Other: 0.5% SLS in sterile distilled water
Other: 0.1% SLS in sterile distilled water
Other: Patch only